News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Media Contact:
Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc
Potential new Digital Medicine consists of Otsuka’s ABILIFY® (aripiprazole) embedded with the Proteus ingestible sensor, for serious mental illnessDrug/device product digitally records medication ingestion and, with patient consent, shares information with patient’s healthcare providers and selected family and friendsIf approved by the FDA, Digital Medicine would provide patients and
Primary and key secondary endpoints were positive for tolvaptan vs. placebo in an additional Phase 3 clinical trial that examined the efficacy and safety of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD)The data are intended to address the Complete Response Letter (CRL) issued by the FDA for a New Drug Application (NDA) for tolvaptan in ADPKD in 2013Trial results will be
Otsuka Pharmaceutical Co., Ltd (Otsuka) and Teva Pharmaceutical Industries, Ltd. (Teva) announce an agreement covering Japan for Otsuka to develop and commercialize Teva’s investigational drug candidate fremanezumab (TEV-48125), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine. Fremanezumab is administered monthly as a subcutaneous
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce top-line results from two phase III clinical trials evaluating the efficacy, safety and tolerability of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer’s type. The primary endpoint of both trials was change from baseline in the Cohen-Mansfield Agitation Inventory (CMAI)